Insider Transactions in Q3 2021 at Nrx Pharmaceuticals, Inc. (NRXP)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2021
|
Robert Besthof Interim CEO |
SELL
Open market or private sale
|
Direct |
40,000
-62.78%
|
$440,000
$11.76 P/Share
|
|
Sep 02
2021
|
Alessandra Daigneault General Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
31,584
+39.71%
|
$94,752
$3.07 P/Share
|
|
Aug 26
2021
|
Herbert Raymond Mc Master Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,300
+50.0%
|
$36,600
$2.22 P/Share
|
|
Aug 23
2021
|
Alessandra Daigneault General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
33,715
-100.0%
|
$438,295
$13.11 P/Share
|
|
Aug 19
2021
|
Alessandra Daigneault General Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
27,395
+44.83%
|
$82,185
$3.07 P/Share
|
|
Aug 16
2021
|
Robert Besthof Interim CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
63,710
+50.0%
|
$0
$0.2 P/Share
|
|
Jul 16
2021
|
Daniel C. Javitt > 10% Shareholder |
SELL
Bona fide gift
|
Indirect |
869,188
-3.16%
|
-
|